JP2024501764A - 併用療法 - Google Patents

併用療法 Download PDF

Info

Publication number
JP2024501764A
JP2024501764A JP2023540910A JP2023540910A JP2024501764A JP 2024501764 A JP2024501764 A JP 2024501764A JP 2023540910 A JP2023540910 A JP 2023540910A JP 2023540910 A JP2023540910 A JP 2023540910A JP 2024501764 A JP2024501764 A JP 2024501764A
Authority
JP
Japan
Prior art keywords
formula
compound
salt
disease
cardiomyopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501764A5 (https=
Inventor
ポール チェンバリン，
ジャイクリシュナ パテル，
Original Assignee
インブリア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インブリア ファーマシューティカルズ， インコーポレイテッド filed Critical インブリア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024501764A publication Critical patent/JP2024501764A/ja
Publication of JP2024501764A5 publication Critical patent/JP2024501764A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2023540910A 2021-01-06 2022-01-05 併用療法 Pending JP2024501764A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163134243P 2021-01-06 2021-01-06
US63/134,243 2021-01-06
US202163147801P 2021-02-10 2021-02-10
US63/147,801 2021-02-10
PCT/US2022/011336 WO2022150403A1 (en) 2021-01-06 2022-01-05 Combination therapies

Publications (2)

Publication Number Publication Date
JP2024501764A true JP2024501764A (ja) 2024-01-15
JP2024501764A5 JP2024501764A5 (https=) 2025-12-26

Family

ID=82358297

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540910A Pending JP2024501764A (ja) 2021-01-06 2022-01-05 併用療法

Country Status (8)

Country Link
US (1) US20240082242A1 (https=)
EP (1) EP4274436A4 (https=)
JP (1) JP2024501764A (https=)
KR (1) KR20230129250A (https=)
AU (1) AU2022205937A1 (https=)
CA (1) CA3206848A1 (https=)
IL (1) IL304054A (https=)
WO (1) WO2022150403A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
EP4146215A4 (en) * 2020-05-04 2024-05-01 Imbria Pharmaceuticals, Inc. DOSAGE METHODS FOR TREATMENT OF CARDIOVASCULAR PROBLEMS
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081361A1 (en) * 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
JP2020527133A (ja) * 2017-06-20 2020-09-03 インブリア ファーマシューティカルズ， インコーポレイテッド 心臓代謝の効率を高めるための組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100285A (en) * 1976-04-09 1978-07-11 Nippon Shinyaku Co., Ltd. N-substituted trialkoxybenzyl piperazine derivatives
US20220168431A1 (en) * 2019-03-18 2022-06-02 Imbria Pharmaceuticals, Inc. Methods of treating cancer using trimetazidine-based compounds
US20210401833A1 (en) * 2020-06-30 2021-12-30 Imbria Pharmaceuticals, Inc. Modified release formulations of modified forms of trimetazidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527133A (ja) * 2017-06-20 2020-09-03 インブリア ファーマシューティカルズ， インコーポレイテッド 心臓代謝の効率を高めるための組成物および方法
WO2020081361A1 (en) * 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds

Also Published As

Publication number Publication date
CA3206848A1 (en) 2022-07-14
IL304054A (en) 2023-08-01
AU2022205937A1 (en) 2023-07-13
US20240082242A1 (en) 2024-03-14
EP4274436A1 (en) 2023-11-15
AU2022205937A9 (en) 2024-09-26
WO2022150403A1 (en) 2022-07-14
EP4274436A4 (en) 2024-12-11
KR20230129250A (ko) 2023-09-07

Similar Documents

Publication Publication Date Title
Watt et al. Intravenous adenosine in the treatment of supraventricular tachycardia: a dose‐ranging study and interaction with dipyridamole.
JP2024501764A (ja) 併用療法
US20120184545A1 (en) Heart-slowing drug containing short-acting beta-blocker as teh active ingredient
US12502389B2 (en) Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
EP3718546A1 (en) Controlled-release formulation
WO2013176223A1 (ja) 炎症性疾患治療用医薬組成物
US20240374584A1 (en) Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
JPH1017478A (ja) 潰瘍性大腸炎の予防又は治療剤
CN116829000A (zh) 组合疗法
KR20090027258A (ko) 부작용이 감소된 약리학적 스트레스 시험 방법, 조성물, 단위 투여형, 및 키트
TWI426923B (zh) 在以多層電腦斷層攝影進行之冠狀動脈攝影方法中依伐布雷定（ｉｖａｂｒａｄｉｎｅ）作為診斷劑之用途
BRPI0717077A2 (pt) Formulações para administração terapêutica de hormonio estimulante da tiróide (tsh)
CN116234555A (zh) 改良形式的曲美他嗪的改良释放制剂
CN119564700B (zh) 帕珠沙星甲磺酸盐在制备治疗急性心肌梗死的药物的用途
CA2566684C (en) Pharmaceutical nitrones
JP5648287B2 (ja) 冠動脈の描出能改善剤
HK1144788A (en) Use of ivabradine as diagnostic agent in the method of coronary angiography by multislice computed tomography

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251031

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20251218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331